chronic hepatitis B
Conditions
Interventions
HBV DNA positive group 1: ETV 0.5 mg/day, 96 weeks
HBV DNA positive group 2:TAF 25mg/d, 96 weeks
HBV DNA positive group 3:ETV0.5mg/d+TAF 25mg/d, 96 weeks
HBV DNA positive group 1:ETV0.5mg/d orTAF 25mg/d+ Peg IFN a, 96 weeks
HBV DNA negative group 2:ETV 0.5 mg/d, 96 weeks
HBV DNA negative group 3:TAF 25mg/d, 96 weeks
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old, male or female; 2. Treated with ETV alone for more than 48 weeks (including patients who had previously been treated with Lamivudine, telbivudine or Adefovir) and are continuing ETV treatment; 3. HBsAg positive, HBeAg positive or negative; 4. Willing to accept treatment and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who received immunomodulatory therapy (such as Interferon) or traditional Chinese medicine anti-fibrotic drugs within 6 months, or who required systematic treatment outside the antiviral drug during the study period; 2. Pregnant women or lactating women 3. A history of mental illness (schizophrenia or severe depression), uncontrolled epilepsy, severe infection, retinal disease, heart failure, chronic obstructive pulmonary disease and other basic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA; | — |
Countries
China
Contacts
Public ContactHu Zhongjie
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed